UK

The UK Biotech Sector and Brexit: Past Performance and Future Prospects

1 April 2018

This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2)…

Barriers to Uptake of Minimal Access Surgery in the United Kingdom

1 March 2018

Surgical practice has and continues to develop at a tremendous pace, reflecting the evolving technological landscape as well as the expanding skillset of the surgical workforce.…

Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market

1 December 2017

This report explores the consequences of the exit of the United Kingdom (UK) from the European Union (EU) on public health in the UK and in…

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

1 March 2017

The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening…

Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets

1 March 2017

Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ,…

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

12 January 2016

This Research Paper reports the views of 179 members of the UK general public about important aspects of health that they consider to be missing from the five dimensions of the EQ-5D instrument.

A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications

1 May 2016

NICE’s decisions exert an influence on the allocation of fixed NHS budgets, but decisions for different types of health interventions (for example drugs and devices) are…

Multi-indication Pricing: Pros, Cons and Applicability to the UK

1 October 2015

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if…

Exploring the Interdependencies of Research Funders in the UK

1 July 2014

As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their…